Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [25][31] - The company generated over $329 million in cash from operations in 2025 and ended the year with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [7][31] - GAAP net income for the fourth quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM prescriptions grew by 20% year-over-year, generating $148.9 million in net revenue, up 48% compared to pro forma 2024 revenue [6][26] - The pain portfolio generated $631.7 million in 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [7][21] - Belbuca net revenue was $221.7 million in 2025, up 5% year-over-year, while Xtampza ER net revenue was $199.3 million, up 4% year-over-year [26][27] Market Data and Key Metrics Changes - Jornay's market share of the long-acting branded methylphenidate market grew to nearly 26% in the fourth quarter, up 6.5 percentage points year-over-year [18] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [18][19] - The company secured new formulary access under a major commercial healthcare plan, increasing Jornay's coverage by an estimated 4.5 million covered lives [21] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and strategically deploying capital to enhance shareholder value [4][10] - The company aims to expand and diversify its portfolio through business development, debt repayment, and opportunistic share repurchases [11][33] - The company is committed to maximizing the life cycle of its pain portfolio and ensuring medicines remain accessible to patients [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver near and long-term growth, emphasizing the strong financial foundation provided by the pain portfolio and the growth potential of Jornay [12][37] - The company expects total product revenues in 2026 to be in the range of $805 million to $825 million, reflecting a 4% increase year-over-year driven by Jornay growth and durable revenues from the pain portfolio [31][32] - Management noted that they do not foresee significant competitive developments that could impact Jornay demand, highlighting its differentiated delivery technology [41] Other Important Information - The company published its 2025 ESG report, showcasing its commitment to social responsibility alongside financial success [5] - The company closed a $980 million syndicated credit facility, improving interest rates and providing flexibility for future business development opportunities [8][34] Q&A Session Questions and Answers Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management stated that they do not see any material changes in competitive dynamics that could impact Jornay demand, emphasizing its unique delivery technology [41] Question: Can you help us frame how you're thinking about the ramp to peak sales for Jornay? - Management noted that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing activities throughout 2026 [45] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are highly promotionally sensitive, and they will continue to invest in these products [47][48]

Financial Data and Key Metrics Changes - Adjusted EBITDA for 2025 reached just over $7 billion, reflecting a mid-single-digit three-year growth CAGR [4] - Adjusted EBITDA for the fourth quarter increased by 2% year-over-year to $1.8 billion, while distributable cash flow decreased by 4% to $1.4 billion due to increased interest expenses [16][17] - The company returned $1.2 billion to unit holders in distributions and unit repurchases during the quarter [16] Business Line Data and Key Metrics Changes - In the crude oil and products logistics segment, adjusted EBITDA increased by $52 million year-over-year, driven by a revised FERC tariff and higher rates [13] - The natural gas and NGL services segment saw adjusted EBITDA decrease by $10 million year-over-year, primarily due to the divestiture of non-core assets and lower NGL prices [14] - Gathered volumes in the natural gas and NGL segment increased by 2% year-over-year, while processing volumes decreased by 1% [15] Market Data and Key Metrics Changes - Natural gas demand in the U.S. is anticipated to grow over 15% through 2030, driven by LNG export capacity expansion and rising power needs [5] - The company is focusing 90% of its growth capital on the natural gas and NGL services segment, particularly in the Permian and Marcellus basins [7] Company Strategy and Development Direction - The company plans to invest $2.4 billion in 2026 to support long-term structural growth, with a focus on natural gas and NGL value chains [5] - The capital plan includes significant projects like the Harmon Creek III gas processing complex and the Secretariat II processing plant, expected to deliver mid-teens returns [9][11] - The company aims to optimize its portfolio through divestitures of non-core assets to align future capital deployment with the strongest return opportunities [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term fundamentals of the energy market and the company's ability to capture value from growth opportunities [8] - The company anticipates growth in 2026 to exceed that of 2025, driven by increased throughput on existing assets and new assets coming online [19] - Management expects to maintain a distribution growth rate of 12.5% for the next two years, supported by disciplined capital deployment [18] Other Important Information - The company ended the quarter with a cash balance of $2.1 billion and plans to utilize this cash in alignment with its capital allocation framework [17] - The company is focused on maintaining a leverage ratio below 4.0x and ensuring distribution coverage remains above 1.3 times [63] Q&A Session Summary Question: Can you talk about your confidence in the mid-teens return target for the project backlog? - Management emphasized strict capital discipline and the expectation of mid-teens returns from capital investments, supporting mid-single-digit growth [24] Question: Can you provide an update on the commercialization of the Northwind synergy projects? - Management noted that the Northwind sour gas facility is critical for future growth and will support both legacy and new volumes [28] Question: How do you view the new opportunities for LPG exports with the recent India-U.S. trade deal? - Management expressed strong demand for NGL and natural gas, viewing the trade deal as supportive of their long-term LPG export strategy [38] Question: Will you consider M&A opportunities in 2026 if the right opportunities arise? - Management confirmed they are open to M&A opportunities that meet their strict capital discipline and strategic alignment criteria [40] Question: How do recent consolidations in the upstream community affect your growth outlook? - Management indicated that recent consolidations do not pose immediate risks to contract renegotiations and will continue to be an important part of their portfolio [48] Question: Is the 2026 growth expectation inclusive of the headwind from the Rockies asset sale? - Management confirmed that the 2026 growth expectation accounts for the headwind from the Rockies asset sale [53] Question: How should we think about capital allocation and leverage moving forward? - Management reiterated their capital allocation philosophy, prioritizing maintenance capital, distribution growth, and growth capital while managing leverage [62]

Core Insights - Federal Realty (FRT) is actively pursuing a capital deployment strategy through acquisitions and dispositions to enhance portfolio quality and long-term value creation [1][6]. Acquisition Activities - FRT acquired two open-air retail centers, Town Center Plaza and Town Center Crossing, in Leawood, Kansas, totaling 550,000 square feet for $289 million, benefiting from strong local demographics and demand from top-tier tenants like Trader Joe's, Apple, and Sephora [2][8]. Disposition of Non-Core Assets - The company sold its Hollywood Boulevard retail portfolio in Los Angeles, comprising 181,000 square feet, for $69 million, and a 108-unit residential building in Santana Row for $74 million, with plans to identify an additional $1 billion in potential asset dispositions [3][8]. Development Projects - FRT is commencing the development of Lot 12, a 258-unit residential project at Santana Row, with an investment of approximately $145 million, aimed at meeting the growing demand for high-quality residential spaces [4][6]. Additional Residential Projects - The company has two more residential projects underway: a 45-unit building in Hoboken, NJ, expected by 2027, and a 217-unit multifamily project in Bala Cynwyd, PA, anticipated by mid-2026, both showing strong early leasing demand [5]. Strategic Focus - FRT's strategy emphasizes capitalizing on expansion opportunities in premium markets, focusing on mixed-use developments that cater to the trend of living, working, and playing in the same area, thereby driving income growth and long-term value [6]. Stock Performance - Over the past three months, FRT's shares have increased by 4.9%, outperforming the industry growth of 3.6% [7].